• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过分子动力学模拟和自由能计算探索 VEGFR2 与三种药物仑伐替尼、索拉非尼和舒尼替尼的结合机制。

Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation.

机构信息

Hunan Province Key Laboratory of Materials Surface & Interface Science and Technology, College of Science, Central South University of Forestry and Technology, Changsha, Hunan, China.

CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

出版信息

Chem Biol Drug Des. 2019 May;93(5):934-948. doi: 10.1111/cbdd.13493. Epub 2019 Feb 19.

DOI:10.1111/cbdd.13493
PMID:30689282
Abstract

Lenvatinib (LEN), sorafenib (SOR), and sunitinib (SUN) are drugs targeting vascular endothelial growth factor receptor 2 (VEGFR2). Despite sharing similar chemical structures and bioactivities, LEN and SOR bind to different functional states of VEGFR2, viz. DFG-in and DFG-out state, respectively. SUN binds to the DFG-out state of VEGFR2 just like SOR but with less potency. Thus, detail binding mechanisms between VEGFR2 and these drugs, especially dynamic interaction, are valuable for future drug design. In the present work, molecular dynamics simulation, essential dynamic analysis, and molecular mechanics/generalized born surface area were performed to these VEGFR2-drugs systems. Rank of calculated binding affinities is in accordance with the experimental data. The binding free energy calculation suggests that van der Waals interaction plays a vital role in the binding. Per-residue free energy decomposition indicates that residues L840, V848, A866, E885, L889, V899, V916, F918, C919, L1035, C1045, D1046, and F1047 play an important role in the binding between VEGFR2 and LEN/SOR. While residues L840, V848, E917, F918, C919, G922, L1035, and F1047 contribute the major hydrophobic interaction for SUN binding to the receptor. Our results also reveal that residue E885/D1046 plays a vital role in binding via forming hydrogen bonds with drugs.

摘要

仑伐替尼(LEN)、索拉非尼(SOR)和舒尼替尼(SUN)是靶向血管内皮生长因子受体 2(VEGFR2)的药物。尽管它们具有相似的化学结构和生物活性,但 LEN 和 SOR 分别结合 VEGFR2 的不同功能状态,即 DFG-in 和 DFG-out 状态。SUN 像 SOR 一样结合 VEGFR2 的 DFG-out 状态,但亲和力较弱。因此,这些药物与 VEGFR2 的详细结合机制,特别是动态相互作用,对于未来的药物设计非常有价值。在本工作中,我们对 VEGFR2-药物系统进行了分子动力学模拟、本质动力学分析和分子力学/广义 Born 表面积分析。计算结合亲和力的顺序与实验数据一致。结合自由能计算表明范德华相互作用在结合中起着至关重要的作用。残基自由能分解表明,残基 L840、V848、A866、E885、L889、V899、V916、F918、C919、L1035、C1045、D1046 和 F1047 在 VEGFR2 与 LEN/SOR 结合中起重要作用。而残基 L840、V848、E917、F918、C919、G922、L1035 和 F1047 对 SUN 与受体的结合贡献主要的疏水性相互作用。我们的结果还表明,残基 E885/D1046 通过与药物形成氢键在结合中起着至关重要的作用。

相似文献

1
Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation.通过分子动力学模拟和自由能计算探索 VEGFR2 与三种药物仑伐替尼、索拉非尼和舒尼替尼的结合机制。
Chem Biol Drug Des. 2019 May;93(5):934-948. doi: 10.1111/cbdd.13493. Epub 2019 Feb 19.
2
Study on novel PtNP-sorafenib and its interaction with VEGFR2.新型 PtNP-索拉非尼及其与 VEGFR2 相互作用的研究。
J Biochem. 2021 Oct 12;170(3):411-417. doi: 10.1093/jb/mvab053.
3
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.RET酪氨酸激酶DFG-out抑制剂的相互作用表征及药效团开发
J Mol Model. 2015 Jul;21(7):167. doi: 10.1007/s00894-015-2708-z. Epub 2015 Jun 6.
4
Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.激酶抑制剂与血管内皮生长因子受体-2(VEGFR-2)活性和非活性构象结合的分子动力学模拟及自由能计算研究
J Mol Graph Model. 2015 Mar;56:103-12. doi: 10.1016/j.jmgm.2014.12.006. Epub 2014 Dec 24.
5
Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.基于分子动力学的深入洞察、结合自由能计算和药效团虚拟筛选以鉴定潜在的血管内皮生长因子受体2(VEGFR2)抑制剂
J Recept Signal Transduct Res. 2019 Oct-Dec;39(5-6):415-433. doi: 10.1080/10799893.2019.1690509. Epub 2019 Nov 22.
6
Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.变构抑制剂与 p38α MAP 激酶结合机制的分子动力学模拟和自由能计算研究。
J Chem Inf Model. 2011 Dec 27;51(12):3235-46. doi: 10.1021/ci200159g. Epub 2011 Nov 18.
7
Using molecular dynamics simulation to explore the binding of the three potent anticancer drugs sorafenib, streptozotocin, and sunitinib to functionalized carbon nanotubes.利用分子动力学模拟探索三种强效抗癌药物索拉非尼、链脲佐菌素和舒尼替尼与功能化碳纳米管的结合。
J Mol Model. 2019 May 14;25(6):159. doi: 10.1007/s00894-019-4024-5.
8
Unbinding pathways of VEGFR2 inhibitors revealed by steered molecular dynamics.定向分子动力学揭示的 VEGFR2 抑制剂的解结合途径。
J Chem Inf Model. 2014 Nov 24;54(11):3124-36. doi: 10.1021/ci500527j. Epub 2014 Oct 23.
9
Reveal the interaction mechanism of five old drugs targeting VEGFR2 through computational simulations.通过计算模拟揭示五种靶向血管内皮生长因子受体2(VEGFR2)的老药的相互作用机制。
J Mol Graph Model. 2020 May;96:107538. doi: 10.1016/j.jmgm.2020.107538. Epub 2020 Jan 16.
10
Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.基于配体的药效团模型构建、EGFR 和 VEGFR2 双重酪氨酸激酶抑制剂的分子对接和分子动力学研究。
Int J Mol Sci. 2020 Oct 21;21(20):7779. doi: 10.3390/ijms21207779.

引用本文的文献

1
Anti-Angiogenic Potential of Marine -Derived Lucknolide A on VEGF/VEGFR2 Signaling in Human Endothelial Cells.海洋来源的Lucknolide A对人内皮细胞中VEGF/VEGFR2信号传导的抗血管生成潜力
Molecules. 2025 Feb 20;30(5):987. doi: 10.3390/molecules30050987.
2
In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors.氨苯蝶啶作为血管内皮生长因子受体-2(VEGFR-2)和c-甲硫氨酸受体(c-Met)潜在双重抑制剂的计算机模拟分析
J Xenobiot. 2024 Dec 14;14(4):1962-1987. doi: 10.3390/jox14040105.
3
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.
乐伐替尼与免疫检查点抑制剂在肝细胞癌中的应用:作用机制、临床疗效及未来展望
J Hematol Oncol. 2024 Dec 21;17(1):130. doi: 10.1186/s13045-024-01647-1.
4
Inhibitory Effect of Phenolic Compounds on Vascular Endothelial Growth Factor-Induced Retinal Endothelial Permeability and Angiogenesis.酚类化合物对血管内皮生长因子诱导的视网膜内皮通透性和血管生成的抑制作用。
Prev Nutr Food Sci. 2024 Sep 30;29(3):321-331. doi: 10.3746/pnf.2024.29.3.321.
5
Insight into antioxidant-like activity and computational exploration of identified bioactive compounds in Talinum triangulare (Jacq.) aqueous extract as potential cholinesterase inhibitors.洞察三角叶马兰(Jacq.)水提物中具有抗氧化样活性的已鉴定生物活性化合物,并通过计算方法探索其作为潜在乙酰胆碱酯酶抑制剂的特性。
BMC Complement Med Ther. 2024 Mar 28;24(1):134. doi: 10.1186/s12906-024-04424-2.
6
Discovery of A Novel Series of Quinazoline-Thiazole Hybrids as Potential Antiproliferative and Anti-Angiogenic Agents.发现新型喹唑啉-噻唑杂合体作为有潜力的抗增殖和抗血管生成剂。
Biomolecules. 2024 Feb 12;14(2):218. doi: 10.3390/biom14020218.
7
New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and study.新型苯并噻唑类杂合体作为潜在的 VEGFR-2 抑制剂:设计、合成、抗癌评价及研究。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2166036. doi: 10.1080/14756366.2023.2166036.
8
The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors.使用机器学习建模、虚拟筛选、分子对接和分子动力学模拟来鉴定潜在的 VEGFR2 激酶抑制剂。
Sci Rep. 2022 Nov 5;12(1):18825. doi: 10.1038/s41598-022-22992-6.
9
Optimizing the Calculation of Free Energy Differences in Nonequilibrium Work SQM/MM Switching Simulations.优化非平衡工作 SQM/MM 切换模拟中自由能差异的计算。
J Phys Chem B. 2022 Apr 21;126(15):2798-2811. doi: 10.1021/acs.jpcb.2c00696. Epub 2022 Apr 11.
10
Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy.血管内皮生长因子受体激活的结构基础及其对疾病治疗的意义。
Biomolecules. 2020 Dec 15;10(12):1673. doi: 10.3390/biom10121673.